Penetration of ceftaroline into the epithelial lining fluid of healthy adult subjects

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 10, 2016, Pages 5849-5857

  Riccobene, Todd A ^a   Pushkin, Richard ^b,d   Jandourek, Alena ^b,e   Knebel, William ^c   Khariton, Tatiana ^a,f  

^a Forest Laboratories LLC   (United States)

^b Cerexa Inc   (United States)

^c Metrum Research Group LLC   (United States)

^d Cempra Pharmaceuticals Inc   (United States)

^e Harborside Financial Center   (United States)

^f Inncelerex   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; CEFTAROLINE FOSAMIL; CEPHALOSPORIN DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION AT STEADY-STATE; CONTROLLED STUDY; COUGHING; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELIMINATION HALF-LIFE; EPITHELIAL LINING FLUID; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RHINORRHEA; VOMITING; BLOOD; BRONCHOALVEOLAR LAVAGE FLUID; CLINICAL TRIAL; CYTOLOGY; DRUG EFFECTS; EPITHELIUM CELL; INTRAVENOUS DRUG ADMINISTRATION;

ADULT; BRONCHOALVEOLAR LAVAGE FLUID; CEPHALOSPORINS; EPITHELIAL CELLS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INJECTIONS, INTRAVENOUS; MALE;

EID: 84992692291     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02755-15     Document Type: Article

References (38)

1. Flamm RK, Sader HS, Farrell DJ, Jones RN. 2012. Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program. Antimicrob Agents Chemother 56:2933-2940. http://dx.doi.org/10.1128/AAC.00330-12.
2. Morrissey I, Ge Y, Janes R. 2009. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with communityacquired pneumonia. Int J Antimicrob Agents 33:515-519. http://dx.doi.org/10.1016/j.ijantimicag.2008.12.005.
3. File TM, Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley IA, Thye DA, FOCUS 1 Investigators. 2011. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 66(Suppl 3):iii19-iii32.
4. File TM, Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley I, Thye D. 2010. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 51:1395-1405. http://dx.doi.org/10.1086/657313.
5. Low DE, File TM, Jr, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley IA, Thye DA, FOCUS 2 Investigators. 2011. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 66(Suppl 3):iii33-iii44.
6. Zhong NS, Sun T, Zhuo C, D'Souza G, Lee SH, Lan NH, Chiang CH, Wilson D, Sun F, Iaconis J, Melnick D. 2015. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, noninferiority with nested superiority trial. Lancet Infect Dis 15:161-171. http://dx.doi.org/10.1016/S1473-3099(14)71018-7.
7. Taboada M, Melnick D, Iaconis JP, Sun F, Zhong NS, File TM, Llorens L, Friedland HD, Wilson D. 2016. Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials. J Antimicrob Chemother 71:862-870. http://dx.doi.org/10.1093/jac/dkv415.
8. Jones RN, Mendes RE, Sader HS. 2010. Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. J Antimicrob Chemother 65(Suppl 4):iv17-iv31.
9. Sader HS, Farrell DJ, Mendes RE, Flamm RK, Castanheira M, Jones RN. 2015. Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013. Diagn Microbiol Infect Dis 82:78-84. http://dx.doi.org/10.1016/j.diagmicrobio.2015.01.015.
10. Bhalodi AA, Crandon JL, Biek D, Nicolau DP. 2012. Efficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model. Antimicrob Agents Chemother 56:6160-6165. http://dx.doi.org/10.1128/AAC.01078-12.
11. Croisier-Bertin D, Hayez D, Da Silva S, Labrousse D, Biek D, Badiou C, Dumitrescu O, Guerard P, Charles PE, Piroth L, Lina G, Vandenesch F, Chavanet P. 2014. In vivo efficacy of ceftaroline fosamil in a methicillinresistant panton-valentine leukocidin-producing Staphylococcus aureus rabbit pneumonia model. Antimicrob Agents Chemother 58:1855-1861. http://dx.doi.org/10.1128/AAC.01707-13.
12. Rennard SI, Basset G, Lecossier D, O'Donnell KM, Pinkston P, Martin PG, Crystal RG. 1986. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 60: 532-538.
13. Forest Pharmaceuticals Inc. 2013. Teflaro (ceftaroline fosamil) injection for intravenous use, prescribing information. Forest Pharmaceuticals Inc., St. Louis, MO, USA.
14. Riccobene T, Khariton T, Knebel W, O'Neal T, Ghahramani P. 2013. Pharmacokinetics (PK) of a single dose of ceftaroline fosamil (CPT-F) in children aged 28 days to 12 years: population PK modelling and simulation to support paediatric dose selection. Abstr 23rd Eur Congr Clin Microbiol Infect Dis, abstr P902.
15. Ahn JE, Karlsson MO, Dunne A, Ludden TM. 2008. Likelihood based approaches to handling data below the quantification limit using NONMEMVI. J Pharmacokinet Pharmacodyn 35:401-421. http://dx.doi.org/10.1007/s10928-008-9094-4.
16. Baldwin DR, Maxwell SRJ, Honeybourne D, Andrews JM, Ashby JP, Wise R. 1991. The penetration of cefpirome into the potential sites of pulmonary infection. J Antimicrob Chemother 28:79-86. http://dx.doi.org/10.1093/jac/28.1.79.
17. Boselli E, Breilh D, Rimmelé T, Poupelin JC, Saux MC, Chassard D, Allaouchiche B. 2004. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 30:989-991. http://dx.doi.org/10.1007/s00134-004-2171-2.
18. Rodvold KA, Nicolau DP, Lodise TP, Khashab M, Noel GJ, Kahn JB, Gotfried M, Murray SA, Nicholson S, Laohavaleeson S, Tessier PR, Drusano GL. 2009. Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole. Antimicrob Agents Chemother 53: 3294-3301. http://dx.doi.org/10.1128/AAC.00144-09.
19. Keel RA, Crandon JL, Nicolau DP. 2011. Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates. Antimicrob Agents Chemother 55:4028-4032. http://dx.doi.org/10.1128/AAC.00372-11.
20. Andes D, Craig WA. 2006. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother 50:1376-1383. http://dx.doi.org/10.1128/AAC.50.4 .1376-1383.2006.
21. MacGowan AP, Noel AR, Tomaselli S, Bowker KE. 2013. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother 57: 2451-2456. http://dx.doi.org/10.1128/AAC.01386-12.
22. MacVane SH, So W, Nicolau DP, Kuti JL. 2014. In vitro activity of human-simulated epithelial lining fluid exposures of ceftaroline, ceftriaxone, and vancomycin against methicillin-susceptible and-resistant Staphylococcus aureus. Antimicrob Agents Chemother 58:7520-7526. http://dx .doi.org/10.1128/AAC.03742-14.
23. Justo JA, Mayer SM, Pai MP, Soriano MM, Danziger LH, Novak RM, Rodvold KA. 2015. Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjects. Antimicrob Agents Chemother 59:3956-3965. http://dx.doi.org/10.1128/AAC.00498-15.
24. Canut A, Isla A, Rodríguez-Gascón A. 2015. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function. Int J Antimicrob Agents 45:399-405. http://dx.doi.org/10.1016/j.ijantimicag.2014.12.023.
25. Dryden M, Wilson D, Iaconis J, Gonzalez J. 2015. A phase III trial of ceftaroline fosamil 600 mg q8h versus vancomycin plus aztreonam in patients with cSSTI with systemic inflammatory response or underlying comorbidities. Abstr 25th Eur Congr Clin Microbiol Infect Dis, abstr O193.
26. Corey GR, Wilcox M, Gonzalez J, Jandourek A, Wilson D, Friedland HD, Das S, Iaconis J, Dryden M. 2015. Ceftaroline fosamil (CPT-F) in patients with acute bacterial skin and skin structure infections (ABSSSI) with systemic inflammatory signs: results across 3 pivotal studies using q8h or q12h. Abstr Intersci Conf Antimicrob Agents Chemother, abstr L-839.
27. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 44:79-86. http://dx.doi.org/10.1086/510079.
28. Muller AE, Punt N, Mouton JW. 2013. Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother 68:900-906. http://dx.doi.org/10.1093/jac/dks468.
29. MacVane SH, Kuti JL, Nicolau DP. 2014. Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 58:1359-1364. http://dx.doi.org/10.1128/AAC.01463-13.
30. Kiem S, Schentag JJ. 2008. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 52:24-36. http://dx.doi.org/10.1128/AAC.00133-06.
31. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. 2005. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191:2149-2152. http://dx.doi.org/10.1086/430352.
32. Bayat S, Louchahi K, Verdière B, Anglade D, Rahoui A, Sorin P-M, Tod M, Petitjean O, Fraisse F, Grimbert FA. 2004. Comparison of 99mTc-DTPA and urea for measuring cefepime concentrations in epithelial lining fluid. Eur Respir J 24:150-156. http://dx.doi.org/10.1183/09031936.04 .00106803.
33. Boselli E, Breilh D, Duflo F, Saux MC, Debon R, Chassard D, Allaouchiche B. 2003. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med 31:2102-2106. http://dx.doi.org/10.1097/01.CCM.0000069734.38738.C8.
34. Baldwin DR. 1996. The penetration of novel intravenous cephalosporins into the lung. J Chemother 8(Suppl 2):S71-S82.
35. Ramani A, Udeani G, Evans J, Jandourek A, Cole P, Smith A, Friedland DH. 2014. Contemporary use of ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia: CAPTURE study experience. J Chemother 26:229-234. http://dx.doi.org/10.1179/1973947814Y.0000000184.
36. Kaye KS, Udeani G, Cole P, Friedland HD. 2015. Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia. Hosp Pract 43:144-149. http://dx.doi.org/10.1080/21548331 .2015.1037228.
37. Udeani G, Guervil DJ, Johnson LB, Kaye KS. 2015. Ceftaroline fosamil for the treatment of hospital-acquired pneumonia (HAP) and ventilatorassociated pneumonia (VAP): CAPTURE study experience. Abstr ID Week 2015, abstr 1817.
38. Pasquale TR, Tan MJ, Trienski TL, File TM, Jr. 2015. Methicillinresistant Staphylococcus aureus nosocomial pneumonia patients treated with ceftaroline: retrospective case series of 10 patients. Chemother 27: 29-34. http://dx.doi.org/10.1179/1973947813Y.0000000156.